Li et al. [16] showed that GLP (100, 200, and 400 mg/kg) treatment improved streptozotocin-induced diabetic nephropathy and reversed the decreased matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 in rats. Here, MMP2 is linked to diabetic kidney disease.